Open and transparent ? Read our concerns over the WHO Expert Working Group process
Treating Too Few, Too Late Read about the case for starting ARV treatment earlier in developing countries click here
An ideal TB test ? Read interview with Access Campaign director
Job openings at the Campaign We are looking for a Medical Innovation Policy Adviser and an EU Policy Advocacy Assistant Read more
|
 |
|
 |
|
 |
The Access Campaign is pushing for new TB drugs and diagnostics to be developed while continuing to call attention to the serious underfunding for TB research.
|
What are the minimum requirements for the ideal TB test ? MSF brought together clinicians, laboratory experts and test developers to pool their experience and come up with an agreed list of specifications. Read more |
|
WHA resolution keeps TB in the spotlight "A good step forward" says Access Campaign director Dr. Tido von Schoen-Angerer about the resolution adopted by delegates to the UN health talks. Much more, however, remains to be done. Read on |
|
I want a TB test that works for me ! Follow the stories of Devindra, Charity, Rolandi and others describing their difficult journey to being diagnosed with TB Click here |
|
In Swaziland 80% of patients with TB are also co-infected with HIV/AIDS and TB is the main cause of death for those with HIV/AIDS. To watch this slide show about breaking the silence surrounding HIV/TB co-infection click here |
New Faces of An Old Disease: The spread of TB through populations already infected with HIV and the emergence of drug-resistant strains of the disease are throwing up yet greater medical challenges. Read TB Background Document 2009 
New Drug Trials for Drug-Resistant TBIn a series of papers published by PLoS, international experts explain how innovative trials in patients with drug resistant TB could speed up delivery of new drugs, explore how to fill up the current TB pipeline with additional promising drugs and call for building of clinical trial capacity in developing countries. Paper on Randomized drug trials |
MSF and Tuberculosis
|
